Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
Eleven patients suffering from arthritis received, in a randomized cross-over study, anti-inflammatory doses of two aspirin formulations: Enpryn, capsules containing enteric-coated pellets; Rhusal, an enteric-coated tablet. No significant difference was found between the two formulations with respect to gastrointestinal microbleeding, plasma salicylate levels and urinary recovery of salicylate. Bioavailability studies carried out on 10 healthy male volunteers demonstrated that absorption from the enteric-coated pellet capsules was sustained and complete.
D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D001682:Biological Availability; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006801:Humans; D012459:Salicylates / Q000097:blood; D013608:Tablets, Enteric-Coated
D012459:Salicylates; D013608:Tablets, Enteric-Coated; D001241:Aspirin